Company wide headcount reduction coming

But major hit for sales

 

AS did the dude.

 

Not surprising. Cut backs at WCL first, followed by elimination of NSS positions in March. Fycompa sales flat despite adding 20 plus NICM positions (overpaid, glorified hospital reps with little or no epilepsy experience) AND a new mono therapy indication. News flash: Fycompa is and always will be a forth or fifth line AED. Leadership sealed Fycompa's fate when they made reps "lead" with the ISI (black box) on every call during launch phase, did not proactively use MSLs in the institutions, and hired a contract sales force (half their reps) to call on C and D target community neurologists. It took 18 months for leadership to realize reps should focus on A/B targets and epileptologists.

Hey Eisai, stick to drug development and license drugs to companies that know how to market.

 

could not have said it better myself, hope PH is the first to go. Feel bad for the reps, hopefully they'll get packages if they don't get canned after mid years.

 

Sadly, these are the times PH usually gets promoted. He is always looking out for #1 and staying a step or two ahead of accountability.

 

Eisai. lol.

 

Hopefully, MC and KO are first.

 

I can't believe there is still an Eisai US business

 

AS did the dude.

 

100% agree
KO and MC are toxic and pathetic

 

mirror mirror on the wall who's the fairest of them all

 

Eisai's semi-annual layoff sale for the holidays again?

 

Does Pace University's most distinguished alumnus (besides the now-deceased pornographer Al Goldstein) get the axe?

 

Having just lost my position with Genentech, I see your opening as a fresh start. Considering where I came from, you have upside potential that many would be happy to embrace.

 

just threw up in my mouth a little

 

Sounds like "sales leadership" posting on their Saturday office day.

 

Does the distinguished Pace University alumnus go too?

 

Eisai has been experiencing a slow death since the great purges of 2011 when the company was at it's peak. Since then it's been chip, chip, chip away. Remember the Belviq fiasco and the elimination of the entire Metabolic division, the company's largest sales force? A small Onc division with a poor reputation in the space, and a feeble Epilepsy division with lackluster products is all that remains of a little known mid-sized pharma company with a name few could correctly pronounce. Sad...

 

NSS's all loose their jobs in March at the latest.

I would hold on to whatever bonus you get.

Quintiles is getting the contract.

NICM's you have 7 months to prove your value.

Erggg not good times.

 

it wouldn't surprise me in the least since they launched Fycompa with quintiles as half the sales force and then replaced all the Eisai metabolic reps with quintiles, that was the end of Eisai's so called values.